We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.93%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$973M
AUM Growth
-$259M
Cap. Flow
-$139M
Cap. Flow %
-14.32%
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$13.3M
2
CI icon
Cigna
CI
+$11.7M
3
BIIB icon
Biogen
BIIB
+$9.55M
4
HUM icon
Humana
HUM
+$6.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.19M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$15.7M
2
BDX icon
Becton Dickinson
BDX
+$14.9M
3
HCA icon
HCA Healthcare
HCA
+$14.6M
4
BSX icon
Boston Scientific
BSX
+$12.9M
5
COO icon
Cooper Companies
COO
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
51
IQVIA
IQV
$39.8B
$5.7M 0.59%
29,000
-19,000
-40% -$4.01M
NUVL
52
DELISTED
Nuvalent
NUVL
$5.68M 0.58%
72,500
-17,500
-19% -$1.63M
UHS icon
53
Universal Health Services
UHS
$10.2B
$5.54M 0.57%
30,900
+22,900
+286% +$4.66M
GKOS icon
54
Glaukos
GKOS
$10.7B
$5.48M 0.56%
36,531
-74,469
-67% -$10.3M
NRIX icon
55
Nurix Therapeutics
NRIX
$2.69B
$5.46M 0.56%
290,000
-10,000
-3% -$229K
EHC icon
56
Encompass Health
EHC
$12.4B
$5.17M 0.53%
56,000
-5,000
-8% -$491K
XNCR icon
57
Xencor
XNCR
$1.6B
$4.5M 0.46%
195,750
-8,000
-4% -$184K
NVO
58
Novo Nordisk
NVO
$209B
$4.3M 0.44%
50,000
-50,000
-50% -$5.41M
INSM icon
59
Insmed
INSM
$29.4B
$4.25M 0.44%
61,500
-68,013
-53% -$4.9M
ESPR
60
DELISTED
Esperion Therapeutics
ESPR
$4.21M 0.43%
1,915,000
-60,000
-3% -$140K
ALNY icon
61
Alnylam Pharmaceuticals
ALNY
$29B
$4M 0.41%
17,000
-33,350
-66% -$8.77M
KRYS icon
62
Krystal Biotech
KRYS
$9.81B
$3.72M 0.38%
23,750
+6,750
+40% +$1.2M
VKTX icon
63
Viking Therapeutics
VKTX
$4.02B
$3.62M 0.37%
90,000
-12,500
-12% -$713K
IMVT icon
64
Immunovant
IMVT
$8.24B
$3.59M 0.37%
145,000
-98,000
-40% -$2.78M
GERN icon
65
Geron
GERN
$949M
$3.54M 0.36%
1,000,000
– –
ACLX
66
DELISTED
Arcellx
ACLX
$3.34M 0.34%
43,500
+11,500
+36% +$993K
MRUS
67
DELISTED
Merus
MRUS
$3.13M 0.32%
74,500
-5,000
-6% -$240K
SNDX icon
68
Syndax Pharmaceuticals
SNDX
$1.82B
$3.07M 0.32%
232,000
-27,500
-11% -$471K
MIRM icon
69
Mirum Pharmaceuticals
MIRM
$6.02B
$3.05M 0.31%
73,755
-31,245
-30% -$1.3M
ARVN icon
70
Arvinas
ARVN
$588M
$2.98M 0.31%
155,500
+25,000
+19% +$607K
ANNX icon
71
Annexon
ANNX
$883M
$2.78M 0.29%
542,500
-17,500
-3% -$108K
CRL icon
72
Charles River Laboratories
CRL
$13.2B
$2.74M 0.28%
14,850
-22,650
-60% -$4.36M
KURA icon
73
Kura Oncology
KURA
$874M
$2.74M 0.28%
314,526
+148,000
+89% +$2.13M
ASTH icon
74
Astrana Health
ASTH
$1.86B
$2.52M 0.26%
+80,000
New +$3.8M
DNTH icon
75
Dianthus Therapeutics
DNTH
$6.25B
$2.49M 0.26%
114,000
-36,000
-24% -$926K
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rhenman & Partners Asset Management held 97 positions worth $973M, down 21% from $1.23B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $139M in Q4 2024, closing 5 positions and reducing 54 holdings. Its most notable exit was Evolent Health, an estimated $7.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Zimmer Biomet worth $13.1M.

  • Rhenman & Partners Asset Management's largest Q4 2024 buy was Zimmer Biomet: 124,000 shares worth $13.1M.
  • Rhenman & Partners Asset Management added most to Cigna in Q4 2024, an estimated $11.7M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2024 reduction was Natera, cutting an estimated $15.7M.
  • Rhenman & Partners Asset Management fully exited Evolent Health in Q4 2024, selling an estimated $7.49M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $973M portfolio in Q4 2024.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 5 in Q4 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 21% quarter-over-quarter to $973M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.